Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey


Turner S. J. , Senol E., KARA A., Al-Badriyeh D., DİNLEYİCİ E. Ç. , Kong D. C. M.

BMC INFECTIOUS DISEASES, vol.13, 2013 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13
  • Publication Date: 2013
  • Doi Number: 10.1186/1471-2334-13-560
  • Journal Name: BMC INFECTIOUS DISEASES
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Keywords: Antifungal agents, Voriconazole, Liposomal amphotericin B, Economic evaluation, Invasive fungal infection, Empiric therapy, ANTIFUNGAL THERAPY, FEBRILE NEUTROPENIA, ECONOMIC-EVALUATION, PERSISTENT FEVER, CASPOFUNGIN, IMPACT

Abstract

Background: Invasive fungal infections (IFI) are associated with considerable expense and mortality on healthcare systems. There is a need to provide evidence of both clinical efficacy and value for money with any health technology. The current pharmacoeconomic evaluation investigated the use of liposomal amphotericin B (LAmB) and voriconazole for the empiric treatment of IFI in the Turkish setting.